Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhejiang Hisun Pharmaceutical Co OCF Margin %?
Zhejiang Hisun Pharmaceutical CoSHSE:600267 -1.18%58 OCF Margin % is 18.86% as of Mar. 2026, which is 31% above its 10-year median of 14.35. GuruFocus rates SHSE:600267 with a GF Score™ of 58/100 and a GF Value™ of ¥8.85 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 964 Drug Manufacturers companies, Zhejiang Hisun Pharmaceutical Co ranks better than 80.19% on this metric.
The historical rank and industry rank for Zhejiang Hisun Pharmaceutical Co's OCF Margin % or its related term are showing as below:
SHSE:600267'
s OCF Margin % Range Over the Past 10 Years
Min: 6.31 Med: 14.35 Max: 21.12
Current: 21.53
During the past 13 years, the highest OCF Margin % of Zhejiang Hisun Pharmaceutical Co was 21.12%. The lowest was 6.31%. And the median was 14.35%.
SHSE:600267's OCF Margin % is ranked better than 80.19% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs SHSE:600267: 21.53
Zhejiang Hisun Pharmaceutical Co OCF Margin % Related Terms
Zhejiang Hisun Pharmaceutical Co OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co OCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Hisun Pharmaceutical Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a OCF Margin % of 18.86% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. This is 31% above median its historical median of 14.35. Over the past decade, Zhejiang Hisun Pharmaceutical Co's OCF Margin % has ranged from 6.31 to 21.12. According to the industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #191 out of 964 companies in the Drug Manufacturers industry, placing it in the top 19.8%.
Is Zhejiang Hisun Pharmaceutical Co's OCF Margin % too high?
Zhejiang Hisun Pharmaceutical Co's current OCF Margin % of 18.86% is 31% above median its 10-year median of 14.35. Over the past 10 years, this metric has ranged from a low of 6.31 to a high of 21.12. The Drug Manufacturers industry median OCF Margin % is 10.04. Zhejiang Hisun Pharmaceutical Co's value of 18.86% is 87.9% above this industry median. Based on the distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #191 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #191 out of 964 companies for OCF Margin %. This places Zhejiang Hisun Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.04. Zhejiang Hisun Pharmaceutical Co's value of 18.86% is 87.9% above this benchmark. Historically, Zhejiang Hisun Pharmaceutical Co's own OCF Margin % has ranged from 6.31 to 21.12 over the past decade. While the company's 10-year median is 14.35 vs. the industry median of 10.04, Zhejiang Hisun Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Hisun Pharmaceutical Co's current OCF Margin % of 18.86% is 87.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Hisun Pharmaceutical Co's current OCF Margin % is 18.86%, which is 31% above median its own 10-year median of 14.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current OCF Margin % is 18.86%, which is 31% above median its 10-year median of 14.35 and 87.9% above the Drug Manufacturers industry median of 10.04. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current OCF Margin % is 18.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
OCF Margin %: 18.86% (31% above median its 10-year median of 14.35)
GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
Industry Position: 87.9% above the Drug Manufacturers median (#191 of 964)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
